DV
Dividend Vision

DMAA — Drugs Made In America Acquisition Corp. Ordinary Shares

Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA)

Total return is 7.5% over the past 1.5 years, 25.4 points behind SPY at 32.9%. Its deepest 1-year drawdown was 0.5%.

DMAA is a recently launched blank-check acquisition company formed to identify and merge with an operating business in the pharmaceutical or healthcare manufacturing sector, with a focus on companies producing drugs in the United States. As a special purpose acquisition company (SPAC), it currently holds cash and has not yet completed a business combination, so it does not generate dividend income or have traditional ETF characteristics like a yield, distribution frequency, or published expense ratio. This vehicle appeals primarily to investors interested in gaining exposure to potential domestic pharmaceutical manufacturing opportunities through a merger or acquisition, though investors should be aware of the risks inherent in SPAC structures, including dilution and execution risk.

DMAA key facts

Asset type
Stock
Asset class
Equity
Inception date
02/25/2025
Last close
$10.71
Market cap
$259,034,656
Average volume
80.0
Payout ratio
0.0
P/E ratio
53.35
Forward P/E
0.0
EPS
$0.20